7JK.F EQL PHARMA AB
- Market cap
- EUR 66.0M
- P/E
- -
- P/B
- 2.85x
- ROE
- -3.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is 7JK.F undervalued?
Graham numberThe Graham number of EQL PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EQL PHARMA AB fundamental analysis
No fundamental analysis for EQL PHARMA AB yet.
EQL PHARMA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Full company profileEQL PHARMA AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EQL PHARMA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 410M | 260M | 264M | 374M | 433M | 528M |
| Gross Profit | 95.7M | 116M | 115M | 156M | 163M | 148M |
| Operating Income | 38.6M | 41.1M | 32.2M | 66.4M | 47.4M | 17.7M |
| EBITDA | - | 41.3M | 43.1M | 79.2M | 67.7M | 17.7M |
| Net Income | 31.5M | 30.9M | 22.7M | 43.1M | 12.5M | -9.93M |
| EPS | 1.09 | 1.06 | 0.78 | 1.48 | 0.42 | -0.34 |
| Balance Sheet | ||||||
| Total Assets | 238M | 286M | 374M | 809M | 851M | 813M |
| Total Liabilities | 114M | 131M | 196M | 588M | 584M | 550M |
| Shareholders' Equity | 124M | 155M | 178M | 221M | 267M | 262M |
| Cash & Short-term Investments | 41.2M | 44.4M | 20.5M | 82.4M | 86.8M | 52.4M |
| Cash Flow | ||||||
| Operating Cash Flow | 41.8M | 27.6M | -11.4M | -24.7M | 28.4M | -10.2M |
| Capital Expenditure | 22.1M | 20.5M | 66.3M | 246M | 67.2M | 49.1M |
| Free Cash Flow | 19.7M | 7.11M | -77.7M | -270M | -38.9M | -59.3M |
| Ratios | ||||||
| ROE | 25.5% | 20.0% | 12.8% | 19.5% | 4.7% | -3.8% |
| ROA | 13.3% | 10.8% | 6.1% | 5.3% | 1.5% | -1.2% |
| Net Profit Margin | 7.7% | 11.9% | 8.6% | 11.5% | 2.9% | -1.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
EQL PHARMA AB dividends
EQL PHARMA AB has not paid dividends in the last 5 fiscal years.
Who owns EQL PHARMA AB
- Insiders 57.70%
- Institutions 18.24%
- Public & others 24.06%
- Shares outstanding 29.5M
- Free float 12.8M
EQL PHARMA AB company profile
- Company name
- EQL PHARMA AB
- Ticker
- 7JK.F
- ISIN
- SE0005497732
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 23
- Fiscal year end
- March
- Address
- Stortorget 1, Lund, Sweden, 222 23
- Phone
- 46 46 12 01 70
- Website
- eqlpharma.com
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
EQL PHARMA AB management
8- Mr. Christer Fahraeus B.Sc. Maths, h.c., MSc Bio Eng, Ph.D.Founder & Chairman · born 1965
- Mr. Axel SchorlingPresident & CEO · born 1986
- Mr. Allan Sylvest AasbergChief Financial Officer · born 1975
- Martin KristoffersonChief Operating Officer · born 1978
- Ms. Anna JonssonHead of Accounting · born 1984
- Ms. Anne Drew JensenChief Sales Officer · born 1992
- Mr. Magnus ErrethCQSCO & Supply Chain Officer · born 1977
- Ms. Ivana AntolasChief of Quality · born 1985